Today's Top SOA Links
From the Wires
Therapeutic Solutions International, Inc. Announces New Distribution Agreement With Dentorient Fuss Ltd., of Tel Aviv, Israel
By: Marketwired .
Jan. 29, 2013 09:15 AM
OCEANSIDE, CA -- (Marketwire) -- 01/29/13 -- Therapeutic Solutions International, Inc. (OTCQB: TSOI) announced today the signing of a distribution agreement with Dentorient Fuss Ltd., a dental supply company headquartered in Tel Aviv, Israel.
"We are very pleased that our AMPSA products will be represented by a strong Israeli distributor, as we continue to expand our global reach," stated Tim Dixon, CEO of Therapeutic Solutions International, Inc.
Yolanda Ionescu, Import Coordinator for Dentorient Fuss Ltd., stated, "We are most pleased to enter into this distribution agreement with TSI for their Migran-X® products in Israel and look forward to bringing these products to market, because of how much these products can help patients."
About Dentorient Fuss Ltd.
Dentorient is one of the longest-established companies in Israel engaged in the import, marketing and distribution of dental materials. Their website is www.dentorientfuss.co.il.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is a global manufacturer of the chairside anterior midpoint stop appliance (AMPSA) devices marketed internationally under the trade names Migran-X® and AMPSA CS®, which have helped countless patients prevent debilitating migraine and tension headache pain, bruxism, clenching, grinding, and TMJ disorders. The Migran-X® and AMPSA CS® devices are the most effective non-drug US FDA cleared dental method of migraine prevention on the market today. Dentists fit the AMPSA devices on patients for the treatment of medically diagnosed migraine pain, as well as migraine associated tension-type headaches, in order to reduce their migraine signs and symptoms through the reduction of trigeminally innervated muscular activity, and to prevent bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular activity. In clinical trials reviewed by the US FDA, 82% of medically diagnosed migraine sufferers using the Migran-X device averaged a 77% average reduction of migraine events in the first eight weeks of use. Successful outcomes are produced by reducing head, neck and jaw muscle contraction intensity by nearly 70%. Therapeutic Solutions International also licenses laboratories to manufacture and sell semi-custom AMPSA devices internationally. The Company is also a provider of continuing education programs in the United States focused on AMPSA devices. The Company does not sell AMPSA products in the United States. The Company's corporate website is www.therapeuticsolutionsint.com. Non-US dentists and physicians can order our AMPSA products at www.ordertsoi.com.
Safe Harbor Statement
For more information please contact:
Web 2.0 Latest News
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week